Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Italy Fines Apple €98.6 Million Over App Store Dominance 
AstraZeneca PLC (NASDAQ: AZN) announced on Monday that its Phase III LATIFY clinical trial evaluating ceralasertib in non-small cell lung cancer (NSCLC) did not achieve its primary endpoint. The late-stage study assessed the efficacy and safety of combining ceralasertib, an investigational ATR inhibitor, with Imfinzi (durvalumab), AstraZeneca’s widely used immunotherapy drug.
The LATIFY trial was designed to determine whether the ceralasertib and Imfinzi combination could improve outcomes for patients with NSCLC, one of the most common and deadly forms of lung cancer worldwide. Despite high expectations for the novel treatment approach, the trial results showed that the combination therapy failed to deliver the level of efficacy required to meet the study’s primary goal. As a result, the trial did not demonstrate a statistically significant improvement compared to existing treatment standards.
While the efficacy results were disappointing, AstraZeneca emphasized a key positive aspect of the study. The company reported that the ceralasertib and Imfinzi combination was generally well tolerated by patients, with a safety profile consistent with previous clinical findings. This suggests that, although the treatment did not meet its primary efficacy endpoint in this specific NSCLC population, the drug combination did not raise new safety concerns.
Ceralasertib is an ATR inhibitor developed to target DNA damage response pathways, a strategy believed to potentially enhance the effectiveness of immunotherapy in cancer treatment. Imfinzi, AstraZeneca’s flagship immunotherapy, is already approved for multiple cancer indications, including certain lung cancers. The LATIFY trial aimed to explore whether combining these two therapies could offer additional benefits to patients with advanced NSCLC.
The outcome of the LATIFY Phase III trial highlights the challenges of developing new combination therapies in oncology, particularly in highly competitive areas such as lung cancer treatment. AstraZeneca has not yet disclosed whether further studies of ceralasertib in NSCLC or other cancer types will be pursued. However, the company continues to invest heavily in oncology research, with a broad pipeline focused on innovative cancer therapies.
For investors and the medical community, the LATIFY trial results represent a setback but also underscore the importance of rigorous clinical testing in advancing cancer treatment options.
